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Abstract 
Objectives: The objectives were to determine the prevalence of  total and specific sexual dysfunction among psychiatric out-pa-
tients taking psychotropic medication, assess its relationship with some demographic and clinical variables, determine the effect 
of  sexual dysfunction on subject’s self- esteem and compliance with medication.
Methods: This descriptive, cross-sectional study was conducted in the psychiatric out-patient clinic of  a Tertiary Care Teaching 
Hospital in Benin City. The International Index of  Erectile Functioning (IIEF), Rosenberg’s self  esteem scale and a socio-de-
mographic and clinical data questionnaire were administered to 300 participants; 150 (50%) psychiatric male patients and 150 
(50%) controls.
Results: The prevalence of  total sexual dysfunction was 48.7%, while that of  the specific SDs ranged from 20.0% to 39.3%, 
with erectile dysfunction having the highest proportion. Age, marital status, class, dose of  psychotropic medication, poly-phar-
macy and duration of  treatment were significantly associated with SD. Majority of  patient with SD reported poor compliance 
with medication. Self-esteem scores had significant inverse relationship with total SD scores.
Conclusion: Sexual dysfunction is prevalent amongst psychiatric patients taking psychiatric medication and has negative impli-
cations for self-esteem and medication compliance. Routine enquiry about sexual symptoms by physicians and prompt treatment 
of  SD might enhance overall treatment success.
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Introduction
Normal sexual functioning is one of  the most important 
components of  quality of  life and maintenance of  satis-
fying intimate relationship.1 Adequate sexual expression 
is essential to human relationships and provides a sense 
of  wellbeing which potentially contributes to improved 
subjective health and overall quality of  life.2 Poor self-es-
teem and lack of  compliance with medication can be con-
sequent upon perceived loss of  normal sexual function-
ing. According to (ICD-10)3 the term sexual dysfunction 
(SD) describes the inability of  an individual to partici-
pate in a sexual relationship as he or she would wish and 
includes lack of  interest, lack of  enjoyment, failure of  
physiological responses and/or problems with erection.4 
Sexual dysfunction (SD) is common in the general pop-
ulation and studies conducted across different geograph-
ical regions reveal high prevalence rates.5,6,7 However SD 
is more prevalent among mentally ill patients and patients 
taking psychotropic medications than among healthy 
controls.8,9,10,11,12
The high prevalence of  SD among psychiatric patients 
may be related, mostly to two factors.  First, SD may be 
related to the psychopathology of  the psychiatric disor-
der which may impact negatively on patients’ sexual func-
tioning. Epidemiological and clinical studies show that 
schizophrenia and depression are associated with impair-
ment of  sexual function and satisfaction even in untreat-
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ed patients;8 both positive symptoms (e.g hallucination) 
and negative symptoms of  schizophrenia may affect the 
patients interpersonal relationship and impact negative-
ly on their sexual functioning8,10 Aizenberg and his col-
leagues10 reported that majority of  untreated schizophre-
nia patients had a reduced desired for sex compared with 
healthy control group, similarly mood disorders interfere 
with libido and erectile function8
Secondly, SD may be related to treatment with psycho-
tropic medications especially antipsychotics and anti-
depressant and SD caused by psychotropic medication 
has become an increasingly important topic.13 Serretti 
and Chiesa14 reported that both typical and some atyp-
ical antipsychotics are frequently associated with SD. 
Kockotta and Pfeiffer15 reported that SD was worse in 
schizophrenic patients taking antipsychotic medication 
compared with un-medicated patients. Selective sero-
tonin re-uptake inhibitors (SSRI) may delay ejaculation 
and female orgasm and cause decreased libido and erec-
tile impairment16. Thus many patients experience SD as 
a side effect of  psychotropic medications. Although the 
exact mechanism of  psychotropic related SD is poorly 
understood17, the pharmacological profile of  individual 
drugs may play important roles.
Despite the reported high prevalence of  SD among psy-
chiatric patients, most sufferers do not seek help as it is 
often not reported to doctors.18 Factors reported to be 
responsible for this include feeling of  embarrassment, 
shame, fear of  stigmatization and threat to marriage1,18, 
Similarly many physicians are reluctant to engage with 
their patients on issues bothering on sexual functioning. 
Clayton and his colleagues19 cited socio-cultural barriers, 
inadequate training and knowledge about sexual func-
tioning and treatment of  dysfunction, and fear of  being 
misconstrued as the reasons.
The effects of  sexual side effects of  psychotropic med-
ication on patients’ self- esteem and compliance with 
treatment has long been known.20  Untreated SD may 
portend serious implication for the psychiatric patients as 
it further lowers their quality of  life and self- esteem, and 
impact negatively on compliance with medication.Studies 
have shown that sexual functioning is positively correlat-
ed with self-esteem and decreased sexual satisfaction neg-
atively impact self-esteem causing loss of  confidence.20, 21
The negative consequences that untreated SD portends 
for patients wellbeing/quality of  life, self- esteem and 
overall management success underscores the importance 
of  epidemiological studies aimed at identifying sufferers 
and treating them accordingly.
Although many researchers in the western countries have 
surveyed SD among psychiatric patients and have made 
significant contributions to knowledge, awareness and 
data base, there is, as yet, inadequate research in Nigeria 
and sub- Sahara Africa. The few available studies mostly 
adopted restrictive methods by examining patients with 
a specific dysfunction (e.g erectile dysfunction) alone;22-24 
patients with a specific psychiatric diagnosis (e.g psychot-
ic disorders or schizophrenia) alone;11 or patients on 
conventional antipsychotic medicationsalone,11,14 and 
none, to the best of  our literature search, has examined 
the relationship between SD and patients’ self-esteem 
and compliance to psychotropic medications. This study 
was conducted on a broader scale.  Thus the aims of  this 
study were to:  1) determine the prevalence of  total and 
specific SD in male psychiatric patients and compare these 
with the control group, 2) assess the association between 
SD and some demographic and clinical variables,3) deter-
mine the relationship between SD and patients’ self- es-
teem, and 4) determine the relationship between SD and 
compliance with psychotropic medication. It is believed 
that this study will make modest contributions to knowl-
edge about SD among psychiatric patients and bridge the 
gap in data base especially in Nigeria and Africa.
Materials and methods
Study design
This study was conducted at the psychiatric out-patient 
clinic of  a teaching hospital in Benin, Nigeria.  The hos-
pital is a foremost tertiary institution in the city and the 
entire Edo State.  It receives referrals from private, pri-
mary and secondary health care facilities from within and 
outside the geopolitical zone. The out-patient clinics are 
run three times a week for follow up consultations for pa-
tients that are mostly mentally stable. Information from 
the medical records department of  the hospital showed 
that about 20 patients with a variety of  psychiatric diag-
noses attended the out-patient clinic every clinic day. A 
cross sectional and descriptive design was employed and 
the study was conducted between May, 2017 and April, 
2018.
Sampling:
The sample size required for the study was calculated 
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using the formula for descriptive cross-sectional study.25 
Prevalence value of  16% reported among male psychiat-
ric patients in a previous study in Nigeria9 was used and 
a confidence interval of  95% was assumed. The calculat-
ed minimum size was 206. However, 50% of  the value 
(103) was added in anticipation of  possible rejection of  
questionnaires that would be badly filled. Thus 309 ques-
tionnaires were administered to consecutive attendees at 
the out-patient clinic and their relatives (who served as 
control).
Measures
The International Index of  Erectile Functioning (IIEF), 
the Rosenberg’s self- esteem scale and a socio-demo-
graphic and clinical data questionnaire were used to as-
sess the participants.
The International Index of  Erectile Function Question-
naire (IIEF)26: This is a self-report questionnaire for as-
sessing male sexual functions.  It was developed by an In-
ternational Panel of  experts through an extensive review 
of  the literature and existing questionnaires in addition 
to detailed interview of  men with sexual dysfunction and 
their partners.22,26 The instrument consists of  15 ques-
tions which are divided into five domains; each domain 
addresses a unique dimension of  sexual function: Erec-
tile Function (Q1-5, 15), (Orgasmic Function (Q9,10), 
Sexual Desire (Q11, 12), Intercourse Satisfaction (Q6-8), 
and overall satisfaction (Q13,14), Q1-10 are rated on a 
6-point Likert-type scale (0-5) with  0 indicating no sex-
ual activity or no attempt; while Q11-15 are rated on a 
5-point scale (1-5). Domain scores are computed by sum-
ming the scores for individual items in each domain. Total 
IIEF questionnaire scores range from 0 – 75, with higher 
scores indicating better sexual functioning. Responses to 
each question are based on a man’s experience over the 
past 4 weeks. The IIEF has been used by previous au-
thors in Nigeria 6,9,24 and a reliabilityoefficient (Cron-
bach’s alpha) of  0.921 was obtained24
The instrument has a scoring algorithm showing the five 
domains of  male sexual dysfunction with their different 
cut off  scores[for example, in the erectile function do-
main, the cut off  scores for the degrees of  erectile dys-
function are: 1-10 (severe); 11-16 (moderate); 17-21 (mild 
to moderate); 22-25 (mild); 26-30 (no dysfunction). For the 
purpose of  this study and for ease of  statistical analysis, 
all degrees of  dysfunction (mild to severe) were consid-
ered as ‘dysfunction’. Thus, a binary variable “dysfunc-
tion/No dysfunction emerged. The same method was 
adopted for all the domains using their respective scor-
ing algorithm. The scoring algorithm has been used by 
previous authors in Nigeria. 11,27Our primary outcome 
measure is the rate of  total SD (all patients with at least 
one type SD) while the secondary outcome measure is 
the rate of  specific (domain) SD.
 
The Rosenberg’s Self-esteem Scale29:  This is a 10–item 
self-report likert-type measure that assesses an individu-
al’s overall sense of  self- worth or self- acceptance.  Re-
sponse options of  the scale range from ‘strongly disagree’ 
to ‘strongly agree’.  The sum of  the ratings assigned to all 
the items, after a reverse scoring of  the positively worded 
items gives the global scores which range from 10 to 40 
with higher scores indicating higher self- esteem. Patients 
were rated as having low self-esteem if  they scored below 
the mean score on the self- esteem scale.
Rosenberg initially found it to have strong internal con-
sistency reliability of  0.93.29 In Nigeria, Okwaraji and his 
colleagues30 established a Cronbach alpha of  0.84 and 
two week test–retest reliability coefficient of  0.76.
A structured questionnaire was designed by the authors 
to elicit information on subjects’ socio- demographic and 
some clinical variables. Information on patients’ compli-
ance with medication was based on patients’ self- report 
and was rated as good or poor.
Ethical considerations
The study protocol was approved by the research and eth-
ics committee of  the University of  Benin Teaching Hos-
pital.  All participants were informed that the study was 
confidential and that participation was voluntary. Verbal 
informed consent was obtained from them.
Participants: Consecutive male attendees at the psychi-
atric out-patient clinic diagnosed with various psychiatric 
disorders based on ICD-10 criteria and stabilized on a 
variety of  psychotropic medications were recruited into 
the study.
Eligibility criteria included
Being diagnosed with a particular psychiatric disorder 
based on ICD-10 diagnostic criteria,
Regular use of, at least, a psychotropic medication in the 
last 6 months,
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Aged between 18 and 60 years,
Willingness to voluntarily participate in the study and 
ability to give informed consent.
Exclusion criteria included
Having a chronic illness such as uncontrolled hyperten-
sion, diabetes mellitus or other                    endocrine 
disorders, cardiovascular disorders e.g. recent myocardia 
infarction
Receiving any therapy, using any medication or substanc-
es that are known to interfere with erectile function.
Procedure:
The self-report questionnaires were administered to 
consecutive male clinic attendees who met the inclusion 
criteria after a clinical assessment of  the patients by the 
authors (who are consultant Psychiatrists) in order to en-
sure their physical and mental fitness for the study. The 
patients’ case files were also reviewed in order to corrob-
orate and supplement patients’ self-reported information 
and retrieve relevant clinical details. The questionnaires 
were also administered to consecutive male relatives/care 
givers who accompanied the patients to the hospital and 
met the inclusion criteria. They acted as control group. 
Retrieved questionnaires were checked for correctness 
and coded.
Statistical analysis:
Data were analyzed using version 16 of  the Statistical 
Package for Social Sciences (SPSS) and descriptive statis-
tics (frequencies and percentages) were computed for the 
variables. Categorical variables were compared using the 
chi square test, while the mean age of  patient and control 
group, were compared using independent sample t-test. 
The Pearson’s correlation analysis was used to assess rela-
tionship between some continuous variables, while logis-
tic regression was employed to determine the risk factors 
for sexual dysfunction. The statistical level of  significance 
was set at the 5% level (P<0.05).
Results
Demographic characteristics of  the subjects
A total of  309 questionnaires were administered and re-
trieved, nine were rejected because they were badly filled, 
thus data from 300 participants 150(50%) psychiatric pa-
tients and 150(50%) controls) were analyzed. The mean 
age of  the patients was 38.43+13.52 years while that of  
the control group was 39.87¬+13.29.  There was no sta-
tistically significant difference between the mean ages of  
the patients and control group (t= -0.926, p= 0.355, 95% 
CI= -4.479 - 1.613). Cross tabulation with Chi2 test also 
revealed that patients and controls did not differ signifi-
cantly on any of  their socio-demographic variables (age, 
marital status, sexual partner and so forth).
Clinical characteristics
Frequency distribution showed that the highest propor-
tion of  the patients (45.39%) had psychotic disorders, 
while the least proportion (7.3%) had somatoform disor-
ders. More than one–third (38.7%) of  the patients were 
being treated with two or more psychotropic drugs (po-
ly-pharmacy) while those on mood stabilizer alone con-
stituted the least proportion (6.7%). The average duration 
of  illness and treatment were 7.41+5.75 and 6.15+5.22 
years respectively while the mean daily dose of  antipsy-
chotic medications (chlorpromazine equivalent) was 297 
+ 165 mg/day. Among patients who reported SD, vast 
majority (78.9%) never discussed the problem with their 
doctors.   
More than one-third (37.3%) of  the patients report-
ed poor compliance with their medications, and among 
them, 32 (57.1%) gave sexual side effects as the reason 
for the poor compliance.  The vast majority of  the pa-
tients (81.3%) reported that their premorbid sexual func-
tioning was satisfactory.
The rate of  SD on the different domains were: Erectile 
dysfunction, 39.3%; orgasmic dysfunction, 20.0%; sexu-
al desire dysfunction, 23.3%; intercourse dissatisfaction, 
26.7% and overall dissatisfaction, 28.7%. Almost half  
(48.7%) of  the patients had at least one type of  SD (total 
SD) (Table 1).
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Table 1: Frequency distribution of the clinical variables of the patients 
 
Variables Frequency (N=150)    n    Percent 
Category of Psychiatric Diagnosis     
Anxiety disorders 13   8.7 
Mood disorders 58 38.7 
Psychotic disorders 68 45.3 
Somatoform disorders 11   7.3 
Class of Psychotropic Medication     
Atypical antipsychotic alone 24 16.0 
Typical antipsychotic alone 20 13.3 
SSRI alone 24 16.0 
Tricyclic antidepressant alone 14   9.3 
Mood stabilizer alone 10   6.7 
Combination (poly-pharmacy) 58 38.7 
Dose of antipsychotic (mg/day) (n=97)*     
<300 50 33.3 
      300-500 36 24.0 
>500 11   7.3 
Duration of Illness (years)     
<5 76 50.7 
      5-10 42 28.0 
>10 32 21.3 
Duration of Treatment (years)     
<5 87 58.0 
      5-10 38 25.3 
>10 25 16.7 
Ever Discussed SD with the Doctor?(n=76)**     
    Yes 16 21.1 
     No 60 78.9 
      
Medication Compliance (Self- report)     
    Good 94 62.7 
    Poor 56 37.3 
Reason For Poor Compliance (n=56)     
     Sexual side effect 32 57.1 
     Other reasons 24 42.9 
      
Premorbid Sexual Functioning     
      Satisfactory 122 81.3 
      Unsatisfactory  28 18.7 
     
     
     
SSRI------- Selective serotonin reuptake inhibitors 
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Table 1: Frequency distribution of the clinical variables of the patients contd. 
 
Variables Frequency (N=150) 
   n Percent 
      
Total Sexual dysfunction***     
      No dysfunction   77 51.3 
      Dysfunction   73 48.7 
Erectile dysfunction     
      No dysfunction   91 60.7 
      Dysfunction   59 39.3 
Orgasmic dysfunction     
      No dysfunction 120 80.0 
      Dysfunction   30 20.0 
      
Sexual Desire dysfunction     
      No dysfunction 115 76.7 
      Dysfunction   35 23.3 
Intercourse Satisfaction dysfunction     
      No dysfunction 110 73.3 
        Dysfunction   40 26.7 
Overall Satisfaction dysfunction     
       No dysfunction 107 71.3 
       Dysfunction   43 28.7 
 *Doseof antipsychotics in chlorpromazine equivalent (mg/day)(Applies to patients on anti- psychotic medication). 
**Applies to patients with SD. 
***Patients with at least one type of SD 
 Average duration of illness and treatment= 7.41+5.75 and6.15+5.22 years respectively. 
Mean dose of antipsychotic medications (Chlorpromazine equivalent) = 297+166 mg/day. 
Comparison of  the rates of  SD on all the domains using 
the Chi2 test showed that the patients had significantly 
higher rates of  SD on all domains than the control group 
(Table 2).
Table 2: Comparison of the rates of SD (total and specific) between patient and control groups 
  
Variables 
GROUP 
χ2 df p-value Patient 
n=150(%) 
Control 
n=150(%) 
 Total Dysfunction*           
    No dysfunction         77(51.3)         39(26.0)     16.470   1 <0.001 
    Dysfunction        73(48.7)       111(74.0)       
 Erectile Dysfunction           
    No dysfunction        91(60.7)       125(83.3)     19.114         1 <0.001 
    Dysfunction        59(39.3)          25(16.7)       
 Orgasmic Dysfunction           
    No dysfunction         120(80.0)       136(90.7)       6.818          1     0.009 
    Dysfunction          30(20.0)          14(9.3)       
 Sexual Desire 
Dysfunction       
    
    No dysfunction        115(76.7)        137(91.3)     12.004          1     0.001 
    Dysfunction          35(23.3)          13(8.7)       
Intercourse Dissatisfaction           
    No dysfunction        110(73.3)        131(87.3)       9.304           1      0.002 
    Dysfunction          40(26.7)          19(12.7)       
Overall 
Dissatisfaction               
    
    No dysfunction        107(71.3)         129(86.0)       9.613             1      0.002 
    Dysfunction          43(28.7)          21(14.0)       
*All patients having at least one type of sexual dysfunction. 
The statistical level of significance was set at the 5% level (P<0.05). 
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Correlates of  sexual dysfunction
Chi2 test revealed that Erectile dysfunction is significant-
ly associated with age (P=0.037), class of  psychotropic 
medication (P=0.001), poly-pharmacy (P=0.000), dose 
of  antipsychotics (0.000), duration of  illness (P=0.000), 
duration of  treatment (P= 0.000). Orgasmic dysfunction 
had significant association with marital status (P=0.033).
Sexual desire dysfunction was significantly associated 
with age (P=0.013), duration of  illness and treatment 
(P=0.009 and 0.044 respectively). Intercourse dissatis-
faction had significant association with marital status 
(P=0.032) and poly-pharmacy (P=0.047).
There was significant association between overall dissat-
isfaction; and marital status (P=0.020), poly-pharmacy 
(P=0.009), dose of  antipsychotics (p=0.000), duration of  
illness and treatment (P=0.007 and 0.007 respectively).
Medication compliance was significantly associated with 
all the domains of  sexual dysfunction while self-esteem 
had significant association with erectile dysfunction (P= 
0.001), and overall dissatisfaction (P= 0.026) (Table 3).
Table 3: Summary of association between specific sexual dysfunctions and some 
demographic/clinical variables 
 
Demographic and 
Clinical variables 
                                Spec
ific Sexual Dysfunction 
Erectile Orgasmic Desire Intercourse 
Satisfaction 
Overall 
Satisfaction 
X2              P X2        P X2            P  X2           P X2          P        
        
Age Group 
(Years) 
<20/21-40/41-60 
6.606,  0.037 .076,.963 8.742, .031   .045, .979 5.844, .054 
Marital Status 
Single/Currently 
married/Previously 
married 
4.219,  0.121  6.830, .033 3.132,  .209 6.873, .032 7.861,  .020 
  
Category of 
Psychiatric 
Disorders 
*Anxiety/Mood/Ps
ychotic/Somatofor
m 
6.017,  .198 2.341, .673 2.656, .617 4.401, .354 3.406,  .492 
Class of 
psychotropic 
medications 
**Atypical/Typical
/SSRI/TCA/Mood 
stabilizers 
 
20.063,  .001 3.479, .627 6.985,  .222 8.723, .121  
  
Logistic regression analysis showed that only dose of  
psychotropic medication independently predicted SD. All 
the variables entered into the logistic model accounted 
for 29.1% to 39.0% of  the variation in sexual dysfunction 
(Table 4). Erectile, orgasmic and intercourse satisfaction 
functions were the three domains with the strongest posi-
tive correlation with overall satisfaction. Erectile function 
scores had highly significant inverse relationship with age 
but highly significant positive correlation with self-esteem 
(Table 5).
African Health Sciences Vol 19 Issue 4, December, 20192979
  Table 4: Predictors of sexual dysfunction (logistic regression)  
 
  *Reference category;Being single, Typical antipsychotic, 
   R2: Coefficient of determination of the logistic model. 
   R2 = 29.1% to 39.0% 
  
 
Table 5: Correlations among domains of sexual functions, age and self esteem 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
**. Correlation is significant at the 0.01 level (2-tailed). 
  
            B  p   Odds                       ratio           (OR)       95% C.I for EXP(B) 
          Lower       Upper 
Age -.020 .578 .980 .914 1.051 
Marital srtatus*   .136       
Currently married 1.706 .058 5.510 .947 32.070 
Previously married .335 .753 1.398 .173 11.307 
Class of psychotropic 
drug* 
  .347       
Atypical antipsychotic -.258 .747 .772 .161 3.707 
Combination therapy -.896 .197 .408 .105 1.590 
Dose of antipsychotic -.005 .017 .995 .991 .999 
Number of drugs .896 .197 2.450 .629 9.345 
Duration of illness -.048 .848 .953 .584 1.555 
Duration of treatment -.120 .644 .887 .534 1.474 
Constant 3.025 .018 20.584     
      
              
Age(years) Pearson Correlation -.253** .031 -.147* -.019 -.107 -.099 
Sig. (2-tailed) .000 .587 .011 .745 .065 .088 
Erectile function scores Pearson Correlation   .350** .458** .445** .526** .386** 
Sig. (2-tailed) 
  .000 .000 .000 .000 .000 
Orgasmic function scores Pearson Correlation     .132* .723** .603** .100 
Sig. (2-tailed) 
    .022 .000 .000 .084 
Sexual desire scores Pearson Correlation       .337** .403** .293** 
Sig. (2-tailed) 
      .000 .000 .000 
Intercourse satisfaction scores Pearson Correlation         .682** .155** 
Sig. (2-tailed) 
        .000 .007 
Overall satisfaction scores Pearson Correlation           .228** 
Sig. (2-tailed) 
          .000 
Self-esteem scores Pearson Correlation             
Sig. (2-tailed)             
Discussion
This study examined sexual dysfunction among patients 
attending a psychiatric out-patient clinic in Benin City, 
Nigeria. The patients’ mean age of  38.43 years is note-
worthy; it is within the reproductive and sexually active 
age group. Thus sexual difficulties could be an important 
source of  concern to the respondents.
African Health Sciences Vol 19 Issue 4, December, 2019 2980
Prevalence of  sexual dysfunction
The prevalence rate of  total SD (patients with at least 
one form of  SD) found in this study (48.7%) is similar 
to the rates found in some previous studies.8,9 The rates 
of  the specific SDs are also within  the range reported by 
Oyekanmi and his colleagues.11 Also similar to the reports 
of  some previous authors, erectile dysfunction was the 
commonest type of  specific sexual dysfunction.11 Howev-
er, some researchers have found rates that were higher13,18 
than those found in this study. Variation in reported rates 
of  SD reflects differences in study population, method 
of  enquiry and types of  dysfunction being assessed.
The prevalence rates of  total and all the specific SD were 
significantly higher in the patient group than in the con-
trol group. This finding is in keeping with previous report 
that SD is more prevalent among mentally ill patients and 
patients taking psychotropic medications than among 
healthy controls.8.9
The relatively higher prevalence of  SDs (total and specif-
ic) found in this study portends important implications 
for clinical practice; clinical experience suggests that SD 
among psychiatric patients has been underestimated; 
clinicians often do not enquire about sexual problems, 
worse still, most patients do not spontaneously report 
their sexual difficulties. In this study, less than one- third 
(21.1%) of  the patients with SD never discussed their 
sexual problems with their doctors. Consequently, pa-
tients suffer the distressing effect of  SD in silence with 
its attendant negative effect on compliance with medica-
tions. Awareness of  the prevalence of  SD in psychiatric 
patients would enhance alertness on the part of  the clini-
cians and improve their attitude towards sexual difficul-
ties in the patients. 
Premorbid sexual functioning
An evaluation of  sexual dysfunction in psychiatric pa-
tients should take into consideration premorbid sexual 
functioning. In this study, 38.3% of  the patients had at 
least one form of  SD, but only 18.7% admitted having 
SD prior to the onset of  the illness. Thus, it is plausible 
to assume that the mental illness or the adverse effect of  
their psychotropic medications, or both, contributed sub-
stantially to the excess proportion of  subjects with SD. 
However, this study could not differentiate the effect of  
mental illness from that of  the psychotropic medications. 
It is advocated that future studies address this concern.
 
Correlates of  SD
This study found a significant association between differ-
ent types of  SD and, age, marital status, class of  psycho-
tropic medication, dose of  anti-psychotics, duration of  
illness and treatment, poor compliance with medication 
and low self-esteem:
Age and SD
Age was found to be associated with only erectile dysfunc-
tion; although age did not independently predict SD, the 
risk of  developing SD increased with age (odds= 0.980) 
and age was significantly inversely correlated with sexual 
performance (IIEF global scores). Previous authors also 
reported an association between age and SD especially 
erectile dysfunction.11
The decrease in hormonal influence and, perhaps, the de-
cline in sexual zest that generally come with ageing may 
be responsible for these findings.
Marital status and SD
Similar to the findings of  this study a significant relation-
ship between marital status and SD have been reported 
by some authors.11 In this study, the married men were 
five times more likely to report SD (especially intercourse 
and overall dissatisfaction) than the single. Married men 
are more likely to be aware of, and sensitive to an existing 
sexual difficulty. Besides the desire to satisfy their spouse 
sexually, SD may heighten anxiety and further impair sex-
ual performance. Thus SD could be more worrisome to 
the married men and more likely to be reported by them.
Antipsychotic medication and SD
This study did not assess the effect of  specific psycho-
tropic medications on SD because larger numbers of  pa-
tients would be required for that purpose rather the ef-
fect of  classes of  psychotropic medications was assessed. 
Significantly higher proportion of  patients on typical an-
tipsychotics than those on atypical and other psychotro-
pic drugs reported SD, similar to previous research find-
ings4,30. The dichotomy of  sexual side effects especially 
between the typical and atypical anti-psychotics may be 
related to the different effects of  antipsychotics on dopa-
minergic signaling, with the typical anti-psychotics having 
more direct dopamine (D2) receptor antagonism and sig-
nificantly increasing circulating prolactin levels while the 
atypical group has less of  an effect on increasing prolac-
tin. Therefore the atypical anti-psychotics seem to carry 
expectations for fewer sexual side effects, an important 
advantage that physicians, especially in Nigeria and other 
developing African countries should utilize to minimize 
SD.
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Dose of  anti-psychotic medication and SD
The mean dose of  anti-psychotic medications (chlor-
promazine equivalents) was significantly higher among 
patients with SD than those without it, and dose of  an-
ti-psychotics independently predicted global SD. Similar 
findings were reported by previous authors.8 These find-
ings highlight the need for physicians to avoid excessive 
dosing and maintain their patients on the minimum ef-
fective dose of  anti-psychotics so as to minimize the risk 
of  SD.
Poly-pharmacy and SD
The use of  more than one psychotropic medication in 
treating a patient was significantly associated with erectile 
dysfunction. Unfortunately, mono-therapy is rarely used 
in current psychiatric practice especially in Nigeria. The 
reason for this is multifactorial, including perceived insuf-
ficient or delayed response to a single psychotropic medi-
cation, presence of  co- morbidity, unremitting symptoms 
or refractory illness episode, and the need to prescribe 
a long acting anti-psychotic in addition to oral medica-
tion on account of  poor medication compliance. In this 
study, more than one-third of  the patients were being 
treated with two or more psychotropic medications. The 
combined effects of  the drugs may increase the risk of  
SD. Similar findings were reported by Harrington and his 
colleagues.30,31 Restricting pharmacotherapy to only abso-
lutely necessary drugs, and for the necessary duration of  
treatment, may reduce the rate of  treatment emergent SD.
SD and compliance with medications
More than one-third (37.3%) of  the patients reported 
poor compliance with their psychotropic medications 
and majority of  them (57.1%) cited perceived sexual side 
effects as the reason for non-adherence. Similarly, Ron-
senberg and his colleagues18 found that the presence of  
side effect affected compliance, and 41.7% of  affected 
men admitted that they stopped their medications at 
some point during treatment due to experience of  side 
effects. SD is distressing and patients are often more con-
cerned with the sexual side effects of  their medication 
than any other side effect.21 In this study, the high rate 
of  reported poor compliance, perhaps, reflects the sexual 
concern of  a population who are predominantly in their 
sexually active age group. These findings underscore the 
imperative of  measures that will reduce the incidence of  
treatment-emergent SD and ensure prompt and adequate 
treatment offfected patients.
SD and self  esteem
Low self-esteem was significantly associated with SD in 
this study. It is worthy of  note though, that low self-es-
teem could be a consequence of  mental illness even in 
patients who do not experience SD. However, untreated 
SD has been found to further lower the self-esteem of  the 
patients.20,21 The findings of  this study are in keeping with 
that knowledge, as the mean self-esteem score was signifi-
cantly lower in patients with SD than those without SD. 
Future studies that will further elucidate the relationship 
between self-esteem, mental illness and SD, perhaps, by 
assessing the differential contribution of  mental illness, 
and SD to the variance in low self-esteem is advocated. 
In particular, low self- esteem was significantly associated 
with erectile dysfunction and overall dissatisfaction. The 
relationship between SD and low self-esteem is, perhaps, 
not surprising considering the socio-cultural relevance of  
adequate sexual functioning. A man’s lack of  capacity to 
satisfy his wife sexually diminishes his sense of  masculin-
ity and self-worth, and may be associated with self-stigma 
leading, invariably, to low self–esteem.  Thus, effective 
treatment to bring about significant improvement in con-
fidence and self-esteem is an important component of  
management.
Inter relationship of  sexual function domains
In this study, erectile function of  the IIEF had strong 
positive relationship with overall satisfaction domain. 
This finding reinforces the important role of  good penile 
erection in sexual activity. Men associate penile erection 
with their identity, masculinity and feeling of  self-worth 
and satisfaction but poor erection hinders or interferes 
with the subjective feeling of  enjoyment at other stages 
of  sexual intercourse. Furthermore, erectile dysfunction 
was the commonest type of  SD in our sample, a finding 
similar to previous reports.21,31 This underscores the need 
for proactive interventions in male psychiatric patients 
with SD especially ED so as to enhance their sexual satis-
faction and quality of  life.
Conclusion 
Rates of  total and specific SD were high, and significantly 
higher among the patients than healthy control.  Substan-
tially, SD was underreported to the treating physicians 
and a significant relationship was found between SD and, 
being married, use of  high dose of  antipsychotic drugs, 
use of  typical antipsychotics, poly-pharmacy, duration of  
illness and treatment, poor compliance to medication and 
low self-esteem. 
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Physicians should be aware that SD is prevalent among 
their patients, take sexual history as part of  their routine 
clinical assessment, treat SD promptly and maintain their 
patients on the minimum effective dose of  psychotropic 
drugs in order to prevent poor compliance with medica-
tion, improve self-esteem and enhance overall treatment 
success.It is important to note that, beyond biomedical 
intervention, the role of  psychotherapeutic interventions 
in the management of  SD cannot be ignored. Sex therapy 
techniques, behavioural and cognitive as well as psycho-
dynamic and educational interventions, in group- and in 
couple-setting, have been found to offer some relieving 
effects on sexual dysfunction32.
Limitations of  the study
The results of  this study, although interesting and 
strengthened by the presence of  a control group, are lim-
ited due to a relatively small sample size and the inherent 
challenges associated with hospital based studies. Besides, 
the study was cross sectional in design, thus it was not 
possible to separate the effects of  the mental illness from 
those of  the psychotropic medication.
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